Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet vasodilator-stimulated phosphoprotein flow cytometry

Multiple electrode platelet aggregometry (MEA) adenosine diphosphate (ADP) test is able to detect the platelet response to clopidogrel. The values obtained with MEA ADPtest correlate with those obtained with light transmission aggregometry and peri-interventional MEA ADPtest measurements are highly associated with the risk of early stent thrombosis after percutaneous coronary intervention. The main purpose of the present study was to correlate MEA ADPtest with the VerifyNow P2Y12 analyzer, Platelet VASP flow cytometry and the MEA ADPtest HS in order to test if these assays can substitute for each other. Blood samples from 60 consecutive patients scheduled for coronary angiography before and after administration of 600 mg of clopidogrel were analyzed. The correlation of MEA ADPtest with the other whole blood tests was moderate. The following order for the degree of correlation with MEA ADPtest for postclopidogrel values was found: MEA ADPtest HS (R = 0.83) > VerifyNow P2Y12 (R = 0.47) > Platelet VASP (R = 0.35). Of the 12 patients in the upper quintile of postclopidogrel values according to MEA ADPtest, seven were in the upper quintile according to VerifyNow P2Y12 (P < 0.001), six were in the upper quintile according to MEA ADPtest HS (P = 0.004) and three were in the upper quintile according to VASP (P = 0.63). Therefore, the studied whole blood assays cannot substitute for each other. Each assay with prognostic significance will have to undergo the ultimate test for individualized antiplatelet therapy in form of an adequately powered randomized clinical trial that shows that adjustment of antiplatelet therapy is beneficial for the patient.

[1]  Adnan Kastrati,et al.  Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. , 2009, Journal of the American College of Cardiology.

[2]  S. Smyth,et al.  Platelet function analysis: At the edge of meaning , 2009, Thrombosis and Haemostasis.

[3]  Betti Giusti,et al.  Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay: A 12-Month Follow-Up , 2009, Circulation.

[4]  M. Fromm,et al.  Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. , 2008, Journal of the American College of Cardiology.

[5]  Andrew J. Johnson,et al.  Multiple electrode aggregometry and P2Y12 antagonists , 2008, Thrombosis and Haemostasis.

[6]  Matthew J Price,et al.  Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. , 2008, European heart journal.

[7]  A. Michelson.  P2Y12 Antagonism: Promises and Challenges , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[8]  A. Kastrati,et al.  Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment , 2007, Thrombosis and Haemostasis.

[9]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[10]  Deepak L. Bhatt.  Intensifying platelet inhibition--navigating between Scylla and Charybdis. , 2007, The New England journal of medicine.

[11]  M. Gawaz,et al.  The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score , 2007, Journal of thrombosis and haemostasis : JTH.

[12]  P. Morange,et al.  ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome , 2007, Thrombosis and Haemostasis.

[13]  A. Gori,et al.  Different methodologies for evaluating the effect of clopidogrel on platelet function in high‐risk coronary artery disease patients , 2007, Journal of thrombosis and haemostasis : JTH.

[14]  A. Gori,et al.  Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. , 2007, Journal of the American College of Cardiology.

[15]  F. Neumann,et al.  Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. , 2006, Journal of the American College of Cardiology.

[16]  J. T. ten Berg,et al.  A head‐to‐head comparison between the VerifyNow® P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention , 2006, Journal of thrombosis and haemostasis : JTH.

[17]  A. Wieczorek,et al.  Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness , 2006, Thrombosis and Haemostasis.

[18]  S. Steinhubl,et al.  Clopidogrel treatment prior to percutaneous coronary intervention: when enough isn't enough. , 2006, JAMA.

[19]  Lippincott Williams Wilkins,et al.  ACC/AHA/SCAI Practice Guidelines, February 21, 2006 , 2006 .

[20]  J. Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Circulation.

[21]  J. Geiger,et al.  Monitoring of clopidogrel action: comparison of methods. , 2005, Clinical chemistry.

[22]  Deepak L. Bhatt,et al.  Variability in platelet responsiveness to clopidogrel among 544 individuals. , 2005, Journal of the American College of Cardiology.

[23]  A. Kastrati,et al.  Loading With 600 mg Clopidogrel in Patients With Coronary Artery Disease With and Without Chronic Clopidogrel Therapy , 2004, Circulation.

[24]  Kevin P. Bliden,et al.  Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.

[25]  M. Gawaz,et al.  Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement , 2003, Thrombosis and Haemostasis.

[26]  G. Hankey,et al.  Aspirin resistance: a new independent predictor of vascular events? , 2003, Journal of the American College of Cardiology.

[27]  U. Walter,et al.  Flow Cytometry Analysis of Intracellular VASP Phosphorylation for the Assessment of Activating and Inhibitory Signal Transduction Pathways in Human Platelets , 1999, Thrombosis and Haemostasis.

[28]  Joseph P Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Journal of the American College of Cardiology.